Provide clinical update from U.S. Phase I/II trial for AMT-130
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 27 Feb 2023
- Due
- 30 Jun 2023
- Delivered
- 21 Jun 2023
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“provide a clinical update from our U.S. Phase I/II study in the second quarter of 2023”
What we found
Evidence strength A What the grades mean
The company announced interim data from the U.S. Phase I/II clinical trial of AMT-130 on June 21, 2023, which falls within the second quarter of 2023.
-
A uniQure N.V. 10-Q filed 2023-08-01
“On June 21, 2023, we announced interim data, including up to 24-month follow-up, from 26 patients enrolled in the ongoing U.S. Phase I/II clinical trial of AMT-130.” ✓ confirmed on the page
Market reaction: the shares moved -4.9% against the S&P 500 over the three sessions around the disclosure (31 Jul 2023 to 3 Aug 2023). What this measures
Checked 1 Oct 2026.
Commitment lineage
Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.
- Deadline drift +731 days
- 4 versions
-
Version 1 · original · stated 27 Feb 2023
Deadline 30 Jun 2023 (“in the second quarter of 2023”)
-
Version 2 · stated 1 Aug 2023
Deadline 31 Dec 2023 (“the fourth quarter of 2023”) · wording expected
“In the fourth quarter of 2023, the Company plans to provide a clinical update from the U.S. and European Phase I/II studies of AMT-130”
-
Version 3 · stated 7 May 2024
Deadline 30 Jun 2024 (“mid-2024”) · wording expected
“In mid-2024, the Company expects to provide an update from its ongoing Phase I/II clinical trials of AMT-130.”
-
Version 4 · stated 1 Aug 2024
Deadline 30 Jun 2025 (“in mid-2025”) · wording expected
“The Company expects to provide an additional interim update from its ongoing Phase I/II clinical trials of AMT-130 in mid-2025.”
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Product other
- Indicative materiality
- Low rules
- Action
- Provide
- Deliverable
- AMT-130 clinical update
- Where
- United States
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you uniQure N.V.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-QURE-001820 · Corrections policy